Quality of life in patients with advanced cancer: Differential association with performance status and systemic inflammatory response

Journal of Clinical Oncology

Volumn 34, Issue 23, 2016, Pages 2769-2775

  Laird, Barry J A ^a,d   Fallon, Marie ^d   Hjermstad, Marianne J ^a,c   Tuck, Sharon ^d   Kaasa, Stein ^a,c   Klepstad, Pål ^a,b   McMillan, Donald C ^e  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN;

ADULT; ADVANCED CANCER; AGED; APPETITE; ARTICLE; BREAST CANCER; CANCER PAIN; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DYSPNEA; EASTERN COOPERATIVE ONCOLOGY GROUP CLASSIFICATION; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE C 30; FATIGUE; FEMALE; FEMALE GENITAL TRACT CANCER; GLASGOW PROGNOSTIC SCORE; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; SYMPTOM; URINARY TRACT CANCER; BLOOD; COMPLICATION; METABOLISM; MIDDLE AGED; NEOPLASM; PAIN; PATIENT-REPORTED OUTCOME; SEVERITY OF ILLNESS INDEX; SLEEP; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGED; APPETITE; C-REACTIVE PROTEIN; CONSTIPATION; DIARRHEA; DYSPNEA; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PAIN; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SLEEP; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84981166235     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.7742     Document Type: Article

References (29)

1. Fayers PM, Machin D: Quality of Life: The Assessment, Analysis and Interpretation of Patient-Reported Outcomes (ed 2). Chichester, United Kingdom, John Wiley & Sons, 2007
2. Velikova G, Coens C, Efficace F, et al: Health-related quality of life in EORTC clinical trials: 30 years of progress from methodological developments to making a real impact on oncology practice. Eur J Cancer 10:141-149, 2012
3. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
4. MacLeod C (ed): The clinical evaluation of chemotherapeutic agents in cancer, in Evaluation of Chemotherapeutic Agents. New York, NY, Columbia University Press, 1949, pp 196
5. Buccheri G, Ferrigno D, Tamburini M: Kar-nofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32 A: 1135-1141, 1996
6. Wallach D, Kang TB, Kovalenko A: Concepts of tissue injury and cell death in inflammation: A historical perspective. Nat Rev Immunol 14:51-59, 2014
7. Laird BJ, Scott AC, Colvin LA, et al: Cancer pain and its relationship to systemic inflammation: An exploratory study. Pain 152:460-463, 2011
8. Laird BJ, McMillan DC, Fayers P, et al: The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist 18:1050-1055, 2013
9. McMillan DC: The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev 39:534-540, 2013
10. Laird BJ, Kaasa S, McMillan DC, et al: Prognostic factors in patients with advanced cancer: A comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res 19:5456-5464, 2013
11. Miura T, Matsumoto Y, HamaT, et al: Glasgow prognostic score predicts prognosis for cancer patients in palliative settings: A subanalysis of the Japan-prognostic assessment tools validation (J-ProVal) study. Support Care Cancer 23:3149-3156, 2015
12. De Paula Pantano N, Paiva BS, Hui D, et al: Validation of the Modified Glasgow Prognostic Score in advanced cancer patients receiving palliative care. J Pain Symptom Manage 51:270-277, 2016
13. Klepstad P, Fladvad T, Skorpen F, et al: Influence from genetic variability on opioid use for cancer pain: A European genetic association study of 2294 cancer pain patients. Pain 152:1139-1145, 2011
14. Hjermstad MJ, Lie HC, Caraceni A, et al: Computer-based symptom assessment is feasible in patients with advanced cancer: Results from an international multicenter study, the EPCRC-CSA. J Pain Symptom Manage 44:639-654, 2012
15. Johnson C, Aaronson N, Blazeby J, et al: Guidelines for Developing Questionnaire Modules. (ed 4). Brussels, Belgium, EORTC Quality of Life Group, 2011
16. Fayers PM, Aaronson NK, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual (ed 3). Brussels, Belgium, European Organisation for Research and Treatment of Cancer, 2001
17. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
18. Ma C, Bandukwala S, Burman D, et al: In-terconversion of three measures of performance status: An empirical analysis. Eur J Cancer 46:3175-3183, 2010
19. Diakos CI, Charles KA, McMillan DC, et al: Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15:e493-e503, 2014
20. Roxburgh CS, McMillan DC: Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal trans-duction pathway in patients with cancer. Transl Res 167:61-66, 2016
21. Sala D, Sacco A: Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases. Curr Opin Clin Nutr Metab Care 19:171-176, 2016
22. Weiss U: Inflammation. Nature 454:427, 2008
23. Mantovani A, Allavena P, Sica A, et al: Cancer-related inflammation. Nature 454:436-444, 2008
24. Ando K, Takahashi F, Kato M, et al: Tocilizu-mab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer. PLoS One 9:e102436, 2014
25. Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807, 2012
26. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
27. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
28. McAllister SS, Weinberg RA: The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 16:717-727, 2014
29. Evans JD: Straightforward Statistics for the Behavioral Sciences. Pacific Grove, CA, Brooks/Cole Publishing, 1996